| Basics |
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.
|
| IPO Date: |
December 1, 2006 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$624.99M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.58 | 2.30%
|
| Avg Daily Range (30 D): |
$0.39 | 3.61%
|
| Avg Daily Range (90 D): |
$0.29 | 3.12%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.54M |
| Avg Daily Volume (30 D): |
1.12M |
| Avg Daily Volume (90 D): |
1.02M |
| Trade Size |
| Avg Trade Size (Sh.): |
109 |
| Avg Trade Size (Sh.) (30 D): |
82 |
| Avg Trade Size (Sh.) (90 D): |
84 |
| Institutional Trades |
| Total Inst.Trades: |
4,954 |
| Avg Inst. Trade: |
$2.5M |
| Avg Inst. Trade (30 D): |
$1.04M |
| Avg Inst. Trade (90 D): |
$.99M |
| Avg Inst. Trade Volume: |
.08M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.2M |
| Avg Closing Trade (30 D): |
$1.1M |
| Avg Closing Trade (90 D): |
$1.03M |
| Avg Closing Volume: |
108.52K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$1.42
|
$.96
|
$-.22
|
|
Diluted EPS
|
$1.31
|
$.91
|
$-.22
|
|
Revenue
|
$ 788.9M
|
$ 231.1M
|
$ 140.9M
|
|
Gross Profit
|
$
|
$ 145.2M
|
$ 74M
|
|
Net Income / Loss
|
$ 75.9M
|
$ 51.2M
|
$ -12M
|
|
Operating Income / Loss
|
$ 118.5M
|
$ 76.5M
|
$ 1.6M
|
|
Cost of Revenue
|
$
|
$ 85.9M
|
$ 66.9M
|
|
Net Cash Flow
|
$ 92.8M
|
$ -21.8M
|
$ 118.2M
|
|
PE Ratio
|
9.08
|
|
|
|
|
|
